Press coverage about Enzo Biochem (NYSE:ENZ) has been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Enzo Biochem earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news articles about the medical research company an impact score of 47.7433993682207 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
ENZ stock traded up $0.17 on Thursday, reaching $6.01. 236,748 shares of the company traded hands, compared to its average volume of 200,082. Enzo Biochem has a one year low of $5.35 and a one year high of $12.04. The firm has a market cap of $262.32, a PE ratio of -120.20 and a beta of 1.04.
Enzo Biochem (NYSE:ENZ) last posted its quarterly earnings data on Monday, March 12th. The medical research company reported ($0.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.01) by ($0.03). The company had revenue of $26.95 million for the quarter, compared to the consensus estimate of $27.35 million. Enzo Biochem had a negative net margin of 1.38% and a negative return on equity of 2.95%.
In other Enzo Biochem news, CEO Elazar Rabbani sold 14,000 shares of Enzo Biochem stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $7.75, for a total value of $108,500.00. Following the completion of the sale, the chief executive officer now owns 1,867,202 shares of the company’s stock, valued at approximately $14,470,815.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Barry W. Weiner sold 11,000 shares of Enzo Biochem stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $7.75, for a total value of $85,250.00. Following the completion of the sale, the chief financial officer now directly owns 1,313,111 shares of the company’s stock, valued at approximately $10,176,610.25. The disclosure for this sale can be found here. 8.90% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Enzo Biochem (NYSE:ENZ) Share Price” was reported by BBNS and is owned by of BBNS. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://baseballnewssource.com/2018/04/05/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-enzo-biochem-enz-stock-price/2028674.html.
Enzo Biochem Company Profile
Enzo Biochem, Inc, an integrated diagnostic bioscience company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics.
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.